For the Inventor, By the Inventor

Enter assignee name

Alameda, CA, United States of America

Celera Corporation

USPTO Granted Patents = 98

% Expired Patents = 38.8

CIPO Patents = 16

EPO Patents = 52

Trademarks = 8

Forward Citations = 582

Loading Chart...

Loading Chart...

84 inventors (with patents filed for the assignee):

James J Devlin (23 out of 39 patents)

Steve Ruben (23 out of 23 patents)

Steven Schrodi (14 out of 14 patents)

4. Olga Iakoubova (13 out of 13 patents)

5. Ann Begovich (13 out of 16 patents)

6. Tao He (12 out of 16 patents)

7. Bruno Domon (11 out of 15 patents)

8. Candy Lee (10 out of 10 patents)

9. Karen Mason (9 out of 9 patents)

10. John Mason (9 out of 16 patents)

11. Yonghong Li (9 out of 9 patents)

12. Dov Shiffman (8 out of 12 patents)

13. Michele Cargill (8 out of 9 patents)

14. Charles E Birse (8 out of 11 patents)

15. Calum MacRae (7 out of 7 patents)

Core Competencies:

Genetic Polymorphisms

Automated Circuit Generation

Cancer Diagnostics

Cardiovascular Diseases

Statin Response

Lung Cancer

Myocardial Infarction

Rheumatoid Arthritis

Breast Cancer

Venous Thrombosis

Liver Fibrosis

Neurodegenerative Diseases

98 patents: Sort by Forward Citations

1. 12141511 - Automated circuit generation (2024-11-12),

2. 12093619 - Automated circuit generation (2024-09-17),

3. 12093618 - Automated circuit generation (2024-09-17),

4. 12079555 - Automated circuit generation (2024-09-03),

5. 12073157 - Automated circuit generation (2024-08-27),

6. 11827937 - Genetic polymorphisms associated with statin response and cardiovascular diseases, methods of detection and uses thereof (2023-11-28),

7. 11814684 - Genetic polymorphisms associated with coronary events and drug response, methods of detection and uses thereof (2023-11-14),

8. 11802164 - Methods and compositions for diagnosing and treating diseases (2023-10-31),

9. 11788143 - Genetic polymorphisms associated with psoriasis, methods of detection and uses thereof (2023-10-17),

10. 11708610 - Genetic polymorphisms associated with cardiovascular disorders and drug response, methods of detection and uses thereof (2023-07-25),

11. 11697850 - Polymorphism in the Apo(a) gene predict responsiveness to acetylsalicylic acid treatment (2023-07-11),

12. 11694007 - Automated circuit generation (2023-07-04),

13. 11408034 - Genetic polymorphisms associated with cardiovascular diseases, methods of detection and uses thereof (2022-08-09),

14. 11401555 - Genetic polymorphisms associated with stroke, methods of detection and uses thereof (2022-08-02),

15. 11361134 - Automated circuit generation (2022-06-14),

Company Overview

Celera Corporation, based in Alameda, California, specializes in the field of genetic polymorphisms, focusing on the development of advanced diagnostic tools. The company is dedicated to enhancing the understanding of genetic variations that influence health conditions, including cancer and cardiovascular diseases. Their innovative technologies aim to improve patient outcomes through personalized medicine, particularly in areas such as statin response and the diagnosis of conditions like lung cancer and rheumatoid arthritis.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

98 Patents

#4 in Alameda, CA

#893 in California

#3,858 in US

#7,925 in the World

Alameda, CA, United States of America

Celera Corporation

Forward Citations = 582

84 inventors:

James J Devlin (23 out of 39 patents)

Steve Ruben (23 out of 23 patents)

Steven Schrodi (14 out of 14 patents)

4. Olga Iakoubova (13 out of 13 patents)

5. Ann Begovich (13 out of 16 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Celera Corporation. Retrieved from https://idiyas.com/company/celera

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…